US-based metagenomics technology firm IDbyDNA has announced the company’s Explify Respiratory test can detect new coronavirus (2019-nCoV).
Currently carried out at IDbyDNA’s Salt Lake City lab, Explify Respiratory is said to be an authorised laboratory-developed test (LDT) for respiratory pathogens, including human coronaviruses.
The test can also detect more than 900 viral, bacterial, fungal and parasitic pathogens.
The company states that its research team has scrutinised in-silico produced samples following the publication of the 2019-nCoV genome.
IDbyDNA has computationally assessed the capability of the test to detect 2019-nCoV, distinguishing it from other human coronaviruses.
The California-based firm also states it has been working alongside the public health authorities, including the Centres for Disease Control and Prevention (CDC), to handle suspected or confirmed 2019-nCoV infections.
The Explify platform, built as next-generation sequencing (NGS)-based metagenomics, allows enhanced pathogen detection and profiling in comparison to conventional PCR testing.
Metagenomics is considered to be more resistant to fast-evolving pathogens, including many viruses and allows immediate adaptation of the test to rising pathogens.
IDbyDNA claims that it has quickly addressed an emerging health threat through its metagenomics for the second time in recent years since the Zika virus epidemic in 2015.
The company developed and determined the performance characteristics of the Explify Respiratory test for approval by the US Food and Drug Administration (FDA).
IDbyDNA is involved in developing transformative metagenomics technology to profile microorganisms and pathogens in any sample, along with identification and knowledge and their role in human health.